126 related articles for article (PubMed ID: 38183829)
1. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
4. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
[TBL] [Abstract][Full Text] [Related]
5. Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples.
Avian A; Clemente N; Mauro E; Isidoro E; Di Napoli M; Dudine S; Del Fabro A; Morini S; Perin T; Giudici F; Cammisuli T; Foschi N; Mocenigo M; Montrone M; Modena C; Polenghi M; Puzzi L; Tomaic V; Valenti G; Sola R; Zanolla S; Vogrig E; Riva E; Angeletti S; Ciccozzi M; Castriciano S; Pachetti M; Petti M; Centonze S; Gerin D; Banks L; Marini B; Canzonieri V; Sopracordevole F; Zanconati F; Ippodrino R
J Transl Med; 2022 May; 20(1):231. PubMed ID: 35581584
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
12. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
[TBL] [Abstract][Full Text] [Related]
13. Validation of EUROArray HPV test using the VALGENT framework.
Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
[TBL] [Abstract][Full Text] [Related]
14. Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening.
Iacobellis M; Violante C; Notarachille G; Simone A; Scarfì R; Giuffrè G
Virol J; 2018 Mar; 15(1):48. PubMed ID: 29558950
[TBL] [Abstract][Full Text] [Related]
15. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
16. Validation of the clinical performance and reproducibility of the NeuMoDx HPV assay self-sample workflow.
Heideman DAM; Berkhof J; Verhoef L; Ouwerkerk C; Smit PW; Oštrbenk Valenčak A; Mlakar J; Poljak M; Steenbergen RDM; Bleeker MCG
J Clin Virol; 2024 Apr; 171():105649. PubMed ID: 38335717
[TBL] [Abstract][Full Text] [Related]
17. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
18. Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening.
Heideman DAM; Oštrbenk Valenčak A; Doorn S; Bonde J; Hillemanns P; Gimpelj Domjanič G; Mlakar J; Hesselink AT; Meijer CJLM; Poljak M
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632634
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
[TBL] [Abstract][Full Text] [Related]
20. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]